LLY.US Omvoh medication approved by Health Canada to treat Crohn's disease

The Zhitong Finance App learned that Lilly (LLY.US) announced on Tuesday that its drug Omvoh (mirikizumab, mirikizumab) has been approved by Health Canada to treat patients with Crohn's disease. Currently Omvoh is approved for the treatment of two types of inflammatory bowel disease, including ulcerative colitis.

Health Canada also approved Omvoh's novel citrate-free subcutaneous formulation containing the same active ingredients as the original Omvoh.

Eli Lilly said that in the VIVID-1 clinical trial, for patients with moderate to severe active Crohn's disease, compared with placebo, Omvoh showed statistically significant and clinically significant curative effects on multiple endpoint indicators, reaching a common primary composite endpoint and all major secondary endpoints.